ofloxacin has been researched along with abt 492 in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akaki, T; Kajitani, H; Sato, K; Shishido, S; Tomioka, H | 1 |
| Almer, LS; Balli, DJ; Beyer, JM; Cai, Y; Flamm, RK; Hensey-Rudloff, D; Nilius, AM; Shen, LL | 1 |
| Danziger, LH; Gunderson, SM; Hayes, RA; Quinn, JP | 1 |
| Hammerschlag, MR; Roblin, PM | 1 |
| Arzamastsev, AP; Firsov, AA; Lubenko, IY; Portnoy, YA; Vostrov, SN; Zinner, SH | 1 |
| Hermsen, ED; Hovde, LB; Konstantinides, GN; Rotschafer, JC | 1 |
| Alferova, IV; Firsov, AA; Lubenko, IY; Portnoy, YA; Smirnova, MV; Zinner, SH | 1 |
7 other study(ies) available for ofloxacin and abt 492
| Article | Year |
|---|---|
Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Topics: 4-Quinolones; Aminopyridines; Anti-Infective Agents; Antitubercular Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium tuberculosis; Ofloxacin; Quinolones; Rifamycins | 2000 |
In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.
Topics: Animals; Anti-Bacterial Agents; Bacteria, Anaerobic; Blood Proteins; Ciprofloxacin; DNA Topoisomerases, Type II; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Protein Binding; Quinolones; Rats | 2003 |
In vitro pharmacodynamic activities of ABT-492, a novel quinolone, compared to those of levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
Topics: Anti-Infective Agents; beta-Lactamases; Colony Count, Microbial; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Haemophilus influenzae; Kinetics; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Ofloxacin; Penicillin Resistance; Quinolones; Streptococcus pneumoniae | 2004 |
The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Chlamydia Infections; Chlamydophila pneumoniae; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Ofloxacin; Quinolones | 2004 |
ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model.
Topics: Algorithms; Anti-Infective Agents; Area Under Curve; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Half-Life; Humans; Levofloxacin; Models, Biological; Ofloxacin; Protein Binding; Quinolones; Staphylococcus aureus | 2004 |
Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.
Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Quinolones; Respiratory Tract Infections; Streptococcus pneumoniae | 2005 |
Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model.
Topics: Anti-Bacterial Agents; Area Under Curve; Ciprofloxacin; Computer Simulation; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Streptococcus pneumoniae; Time Factors | 2005 |